has a long half-life allowing for once-daily dosing in treatment-naive patients and has less pharmacokinetic variability compared with other HIV INSTIs. For treatment-naive patients, dolutegravir ...

Pseudoscience has recently re-emerged in the U.S. While much of it concerns vaccines, an "oldie" is again making the rounds: ...